Last reviewed · How we verify
Shenyankangfu tablets and Losartan potassium 50mg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Shenyankangfu tablets and Losartan potassium 50mg (Shenyankangfu tablets and Losartan potassium 50mg) — Chinese PLA General Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Shenyankangfu tablets and Losartan potassium 50mg TARGET | Shenyankangfu tablets and Losartan potassium 50mg | Chinese PLA General Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Shenyankangfu tablets and Losartan potassium 50mg CI watch — RSS
- Shenyankangfu tablets and Losartan potassium 50mg CI watch — Atom
- Shenyankangfu tablets and Losartan potassium 50mg CI watch — JSON
- Shenyankangfu tablets and Losartan potassium 50mg alone — RSS
Cite this brief
Drug Landscape (2026). Shenyankangfu tablets and Losartan potassium 50mg — Competitive Intelligence Brief. https://druglandscape.com/ci/shenyankangfu-tablets-and-losartan-potassium-50mg. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab